Tag: Weight Loss
Study Identifies Some Modifiable Risk Factors for Ovarian Cancer
Greater parity and ever use of contraception associated with lower risk for ovarian cancer
Prescriptions for Obesity Management Drugs Increasing
Online searches reflect increasing prescription trends; strongest correlation seen for Wegovy and tirzepatide
GLP-1 RAs Efficacious for Weight Loss in Overweight, Obesity Without Diabetes
Adverse events were frequent, and most were gastrointestinal-related, including nausea, vomiting, diarrhea, constipation
Disparities Exist in Use of Obesity-Management Medications
Findings show lower use among Black, Hispanic, and Asian adults versus White adults
FDA Says Shortage of GLP-1 Tirzepatide Is Over
Even Modest Weight Loss Tied to Lower Health Care Spending
Finding seen for adults with overweight or obesity and either employer-sponsored insurance or Medicare coverage
Tirzepatide Yields Sustained Weight Reduction in Obesity, Prediabetes
Three years of tirzepatide also reduced risk for progression to type 2 diabetes compared with placebo
Novo Nordisk CEO Warns of Deaths Linked to Compounded Semaglutide
Expanding Access to Obesity Medications Could Avert 42,000 Deaths/Year
Impact of expanding access to GLP-1 receptor agonists, dual gastric inhibitory polypeptide and GLP-1 receptor agonists quantified
Weight Loss Durable for Years After Bariatric Surgery in Teens
Additionally, durable remission of coexisting conditions seen
